The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Open accessAbstract
PURPOSE: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in patients with sarcoma and report the results of the osteosarcoma cohort. PATIENTS AND METHODS: This trial enrolled patients with progressive metastatic osteosarcoma with measurable disease by RECIST who had received at least one prior line of therapy. Patients were randomly assigned at a ratio of one to one to regorafenib or placebo. Crossover was allowed at time of disease progression. PFS was the primary end point of the study, which was powered to detect a difference of at least 3 months in median PFS. RESULTS: Forty-two patients from 12 centers were enrolled between September 2014 and May 2018. Median age was 37 years (range, 18 to 76 years). Patients had received an average of 2.3 prior therapy regimens. Ten patients receiving placebo crossed over to active drug at time of progression. Study enrollment was stopped early, after a data safety monitoring committee review. Median PFS was significantly improved with regorafenib versus placebo: 3.6 months (95% CI, 2.0 to 7.6 months) versus 1.7 months (95% CI, 1.2 to 1.8 months), respectively (hazard ratio, 0.42; 95% CI, 0.21 to 0.85; P = .017). In the context of the crossover design, there was no statistically significant difference in overall survival. Fourteen (64%) of 22 patients initially randomly assigned to regorafenib experienced grade 3 to 4 events attributed to treatment, including one grade 4 colonic perforation. CONCLUSION: The study met its primary end point, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, clinical trials involving TKIs alone are typically with median PFS ranging from 4 to 6 months accompanied with inevitable development of secondary drug resistance1–5.”
From Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, PFS data for IE in relapsed or refractory osteosarcoma were published several decades before the OLIE study46; thus, the PFS estimate for IE relied on limited historical data from other clinically active agents,15,35,36 and IE performed better than expected relative to these assumptions.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“demonstrating a median progression‐free survival (PFS) of 14.8 weeks in Ewing sarcoma, 10 a median PFS of 3.6 months in osteosarcoma, 11 and a nonprogressive rate at 3 months of 54%, significantly better than results with placebo in chondrosarcoma. 12”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies have demonstrated that multi-targeted tyrosine kinase inhibitor (TKIs) can induce varying degrees of objective responses and prolong progression-free survival (PFS)1–5.”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“BS on average show very low TMB: 0.79–1.96 mutations/Mbase in osteosarcoma, 11 , 17 , 18 , 19 ∼0.2 mutations/Mbas in Ewing sarcoma 19 , 20 and <5 mutations/Mbase in chondrosarcoma with some correlation with grade. 21”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measured
In the citing paper
“Objective response rates were low at 10-15%.”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Of note, dose interruptions and reductions of MTKIs have been frequent across these trials secondary to common toxic effects of this drug class, including hand-foot rash syndrome (palmar-plantar erythrodysesthesia), gastrointestinal toxic effects and hypertension 146,147,148,149,150,151 .”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Four-month progression-free survival (PFS) ranged from 35% to 70% 146,147,148,149,151 .”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Prospective clinical trials evaluated the MTKIs sorafenib, regorafenib, cabozantinib, lenvatinib and apatinib as single agents in patients with relapsed or refractory osteosarcoma, with most enrolled patients falling in the adult age range 146,147,148,149,150,151 (Table 2).”
From Osteosarcoma (2022) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 2×
“Six of 22 patients in SARC028 achieved stable disease, resulting in 12-week PFS of 32%, suggesting activity worth further evaluation of immune checkpoint inhibitors in osteosarcoma.(21) Time Since Start of Crossover Treatment (months) C”
BackgroundSelf-citationLink, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Osteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J., & Davis, L. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 477
Self-citationBielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Atkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Olencki, T. E., Tarazi, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 372
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Grignani, G., Palmerini, E., Ferraresi, V., D’Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71136-2 · Cited by 343
Mross, K. B., Frost, A., Steinbild, S., Hedbom, S., Büchert, M., Fasol, U., Unger, C., Krätzschmar, J., Heinig, R., Boix, O., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1900 · Cited by 335
Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30742-3 · Cited by 331
Mir, O., Brodowicz, T., Italiano, A., Wallet, J., Blay, J., Bertucci, F., Chevreau, C., Piperno-Neumann, S., Bompas, E., Salas, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30507-1 · Cited by 280
Bruix, J., Tak, W. Y., Gasbarrini, A., Santoro, A., Colombo, M., Lim, H.-Y., Mazzaferro, V., Wiest, R., Reig, M., Wagner, A., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.028 · Cited by 255
Ott, P. A., Hodi, F. S., & Buchbinder, E. I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00202 · Cited by 252
Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O., Widemann, B. C., Zwerdling, T., Bomgaars, L., Langevin, A.-M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5381 · Cited by 190
Osteosarcoma over the age of forty
Grimer, R. J., Cannon, S. R., Taminiau, A. M., Bielack, S., Kempf-Bielack, B., Windhager, R., Dominkus, M., Saeter, G., Bauer, H., Meller, I., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00478-1 · Cited by 188
Adenis, A., de la Fouchardière, C., Paule, B., Burtin, P. C., Tougeron, D., Wallet, J., Dourthe, L.-M., Etienne, P.-L., Mineur, L., Clisant, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2440-9 · Cited by 129
Xie, L., Xu, J., Sun, X., Tang, X., Yan, T., Yang, R., & Guo, W. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0542 · Cited by 128
Palmerini, E., Jones, R. L., Marchesi, E., Paioli, A., Cesari, M., Longhi, A., Meazza, C., Coccoli, L., Fagioli, F., Asaftei, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2312-3 · Cited by 98
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
Laverdière, C., Kolb, E. A., Supko, J. G., Gorlick, R. G., Meyers, P. A., Maki, R. G., Wexler, L. H., Demetri, G. D., Healey, J. H., Huvos, A. G., et al. (2003) · Cancer · doi:10.1002/cncr.11563 · Cited by 98
Self-citationPazopanib in relapsed osteosarcoma patients: report on 15 cases
Longhi, A., Paioli, A., Palmerini, E., Cesari, M., Abate, M. E., Setola, E., Spinnato, P., Donati, D. M., Hompland, I., & Boye, K. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1503714 · Cited by 65
Attia, S., Bolejack, V., Ganjoo, K. N., George, S., Agulnik, M., Rushing, D. A., Loggers, E. T., Livingston, M. B., Wright, J. A., Chawla, S. P., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5044 · Cited by 60
Self-citationPrimary versus radiation‐associated craniofacial osteosarcoma
McHugh, J. B., Thomas, D. G., Herman, J. M., Ray, M. E., Baker, L. H., Adsay, V. N., Rabah, R. M., & Lucas, D. R. (2006) · Cancer · doi:10.1002/cncr.22019 · Cited by 46
Taylor, M. H., Rasco, D. W., Brose, M. S., Vogelzang, N. J., Richey, S. L., Cohn, A. L., Richards, D., Stepan, D. E., Dutcus, C. E., Guo, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.6016 · Cited by 38
Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis
Fan, X.-L., Cai, G.-P., Zhu, L.-L., & Ding, G. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s91217 · Cited by 32
Riedel, R. F., Ballman, K. V., Lu, Y., Attia, S., Loggers, E. T., Ganjoo, K. N., Livingston, M. B., Chow, W. A., Wright, J. A., Ward, J. H., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0679 · Cited by 26
Self-citation
Cited by
Sorted by citations
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
New Horizons in the Treatment of Osteosarcoma
Meltzer, P. S., & Helman, L. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2103423 · Cited by 672
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Rédiní, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 494
Metadata
- Authors
- Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, D. K., Riedel, R. F., Attia, S., Mascarenhas, L., & Maki, R. G.
- Affiliations
- Oregon Health & Science University (US)
- Cancer Research And Biostatistics (US)
- Stanford Cancer Institute (US)
- Fred Hutch Cancer Center (US)
- Sarcoma Oncology Center (US)
- Northwestern University (US)
- Levine Cancer Institute (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Indiana University Bloomington (US)
- Mayo Clinic (US)
- Sarcoma Alliance for Research through Collaboration (US)
- Duke Medical Center (US)
- University of Southern California (US)
- Northwell Health (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2019-06-01
- Volume
- 37
- Issue
- 16
- Pages
- 1424-1431
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC7799443
- OpenAlex
- W2941090871
- Cited by
- 268
- References
- 27
- Citations by year
- 2026: 27 · 2025: 29 · 2024: 35 · 2023: 52 · 2022: 36 · 2021: 44 · 2020: 35 · 2019: 9
- FWCI
- 22.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292, P30CA014089)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- regorafenib, metastatic osteosarcoma, multikinase inhibitor, progression-free survival, relapsed sarcoma, crossover design, overall survival, drug safety, colonic perforation
- MeSH terms
- Progression-Free Survival, Adolescent, Adult, Aged, Antineoplastic Agents, Bone Neoplasms, Double-Blind Method, Female, Humans, Male, Middle Aged, Phenylurea Compounds, Pyridines, Osteosarcoma, Time Factors, United States, Disease Progression, Cross-Over Studies, Protein Kinase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
